PALO ALTO, Calif.– MEDiC Life Sciences, a biotechnology company specializing in next-generation functional genomics in 3D cancer models, has acquired a clinical-stage therapeutic program in oncology. The deal marks MEDiC’s first acquisition and highlights its shift toward building a therapeutic pipeline driven by its proprietary SLS™ (Synthetic-Lethal-Gene Signature) biomarker platform.
The acquired program, which has completed Phase I dose escalation studies, targets a key oncogenic driver. Previous efforts in the field have faced challenges in identifying the appropriate patient cohort. By applying its SLS platform, MEDiC said it has optimized patient selection criteria, positioning the program for a more targeted and effective clinical trial strategy. The company plans to advance the asset into biomarker-driven clinical development next year.
“This acquisition carries two major strategic implications for MEDiC,” said Kyuho Han, CEO of MEDiC Life Sciences. “In the near term, it allows us to relaunch a clinical-stage asset in an SLS biomarker-defined patient cohort, creating a Phase II–ready program. In the long-term, its success will serve as a key validation of our platform. By identifying synthetic-lethal biomarkers that enhance the clinical success of cancer therapies, we can unlock a new wave of precision medicines—developed faster, at lower cost, and, most importantly, for the benefit of cancer patients, which remains our highest priority.”
MEDiC’s SLS platform generates millions of biomarker combinations in 3D cancer models and evaluates drug sensitivity to each profile. The approach is designed to improve the odds of clinical success by aligning therapies with patient populations most likely to benefit, potentially accelerating timelines and reducing costs.
The company said it will continue to apply the SLS platform to identify additional acquisition opportunities while also advancing internal first-in-class targets. According to MEDiC, the latest acquisition demonstrates how its technology can uncover undervalued or under-optimized therapeutic assets and help ensure that promising cancer drugs reach the right patient populations.
